Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.

Abstract: The present invention relates to novel compounds that cross the blood-brain barrier and are effective inhibitors of neurological pathogens such as trypanosomes. The invention further relates to the use of these compounds for treating disorders related to trypanosomes and neurological pathogens.

Abstract: A method of treating a hyperkeratotic skin condition includes combining urea powder with a corticosteroid solution comprising a high potency corticosteroid to formulate a compounded topical composition for application to a skin area affected by hyperkeratosis. The corticosteroid solution may be a fluocinolone acetonide solution. The method may also include combining an azole such as clotrimazole.

Abstract: A computerized system for complying with critical infrastructure protection (“CIP”) standards concerning system configuration changes. The system can be used to automatically identify and track changes to computers on the network, improving system security and CIP compliance reporting. In certain embodiments, the system collects system information on servers and workstations using built-in commands. The configuration profiles of these computers/devices can be archived for audit purposes.

Abstract: The present invention is in the field of automatic dishwashing detergent compositions, as well as methods of making and using same. In particular, it relates to an automatic dishwashing detergent composition comprising a new protease. The automatic dishwashing detergent composition provides improved cleaning and finishing. In particular the composition of the invention provides better proteinaceous removal at the same level of other proteases available in the market. This also alternatively allows for the use of a lower level of the protease of the invention and therefore a more cost effective composition.

Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.

Abstract: A support and coupling assembly for a moving screw auger that is used to move grit, such as grit that is used in the blast cleaning industry. The support and coupling assembly includes a hanger bearing assembly with a hanger bearing bracket with an end for engaging a support surface, such as a wall or a ceiling, and a removed end. A roller bearing engages the removed end of the hanger bracket and a shaft is press fit into the roller bearing. A pair of hub assemblies with flights engages the shaft and rotates with the shaft. Connector assemblies engage the hub assemblies to connect the hub assemblies to screw portions on either side of the hanger bearing assembly. The flights on the connector assemblies will cause the grit to speed up as it moves from the screw portion to the connector assembly.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Abstract: A compounded topical solution may include approximately 85% to approximately 95% (v/v) diclofenac sodium topical solution, 1.5% (w/w), and approximately 5% to approximately 15% (v/v) lidocaine hydrochloride topical solution, 4% USP.

Abstract: A method of treating bacterial or fungal nail infections may include mixing an antibiotic or antifungal injectable medication and a diluent to formulate a topical nail composition. The topical nail composition may be administered directly to a nail affected by the bacterial or fungal infection.

Abstract: A method of treating a hyperkeratotic skin condition includes combining contents of a compounded capsule with corticosteroid cream or ointment that includes a high potency corticosteroid to formulate a topical composition for application to a skin area affected by hyperkeratosis. The contents of the capsule may include urea powder, and the corticosteroid cream or ointment may include Clobetasol Propionate Cream or Ointment, Diflorasone Diacetate Cream or Ointment, Amcinonide Cream or Ointment, Betamethasone Dipropionate Cream or Ointment, Desoximetasone Cream or Ointment, Fluocinonide Cream or Ointment, Halcinonide Cream or Ointment, Halobetasol Propionate Cream or Ointment, Mometasone Furoate Cream or Ointment, Flurandrenolide Cream or Ointment, or a combination thereof.

Abstract: A computerized system for complying with critical infrastructure protection (“CIP”) standards concerning system configuration changes. The system can be used to automatically identify and track changes to computers on the network, improving system security and CIP compliance reporting. In certain embodiments, the system collects system information on servers and workstations using built-in commands. The configuration profiles of these computers/devices can be archived for audit purposes.

Abstract: The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine.

Abstract: A compounded topical solution may include approximately 85% to approximately 95% (v/v) diclofenac sodium topical solution, 1.5% (w/w), and approximately 5% to approximately 15% (v/v) lidocaine hydrochloride topical solution, 4% USP.

Abstract: A method of treating or preventing a bacterial infection of a subject may include combining levofloxacin and a diluent to form a treatment solution and topically administering the treatment solution to the subject to bath a skin area with the treatment solution. The treatment solution may include levofloxacin oral solution.

Abstract: A method of treating or preventing a bacterial infection of a subject may include combining linezolid and a diluent to form a treatment solution and topically administering the treatment solution to the subject to bath a skin area with the treatment solution. The treatment solution may be made using linezolid oral tablets.

Abstract: A compounded topical solution may include approximately 85% to approximately 95% (v/v) diclofenac sodium topical solution, 1.5% (w/w), and approximately 5% to approximately 15% (v/v) lidocaine hydrochloride topical solution, 4% USP.

Abstract: A method of compounding a transdermal cream may include grinding one or more tablets of a Non-Steroidal Anti-Inflammatory Drug (NSAID) and one or more nerve depressants, anticonvulsants, or combinations thereof to produce a fine powder. The find powder may be wetted and added to an eutectic mixture of lidocaine and prilocaine in an emulsified topical cream in the form of a lidocaine 2.5%-prilocaine 2.5% cream. The compounded transdermal may include between 0.05% and 0.15% by weight meloxicam, between 1.0% and 5.0% by weight gabapentin, and at least 80% by weight of the lidocaine 2.5%-prilocaine 2.5% cream.

Abstract: In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.

Abstract: System and method for a secure interactive voice response (IVR) includes: receiving a communication from a first party regarding a transaction, over a communication network; connecting the second party with the communication to service the communication; creating an anonymous order entry for the transaction; detecting sensitive information in the communication; isolating the sensitive information in the communication from the second party; route the communication to a secure system for processing of the sensitive information; and reconnecting the communication to complete the transaction